Mode of action of low-molecular-weight heparins in plasma and its consequences for the clinical laboratory by Hemker, H. Coenraad & Beguin, Suzette
  
 
Mode of action of low-molecular-weight heparins in
plasma and its consequences for the clinical
laboratory
Citation for published version (APA):
Hemker, H. C., & Beguin, S. (1994). Mode of action of low-molecular-weight heparins in plasma and its
consequences for the clinical laboratory. In H. Bounameaux (Ed.), Low-Molecular-Weight Heparins in
Prophylaxis and Therapy of Thromboembolic Diseases (pp. 21-42). Marcel Dekker Inc..
Document status and date:
Published: 01/01/1994
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Low-MoIecuIar-Weight
Hep ariglrl Pro p hyl axis
and Therapyof
Thromboembolic Diseases
edited by
Henri Bounameaux
, Geneva University School of Medieine
Univera'ty Hospital of Geneva
Geneva, Switzerland
Marcel Dekker, Inc. New YorkoBaseloHong Kong
Copyright @ 1994 by lv{arcel Dekker, fnc.
2
Mode of Action of Low-Molecular-
Weight Heparins in Plasma and lts
., Consequences for the Ctinical
Laboratory
H. Coenraad Hemker and Suzette B6guin
Cardiovascular Research Institute and IJniversity of Limburg, Maastricht, The
Netherlands
I .  INTRODUCTION
The questions to be posed in heparin pharmacology are the same as those in any
other field of pharmacology: what are the relevant concentrations of the acting
substance at the relevant site and what are the relevant functions of the body that
are influenced by these substances? Then, what is the relationship between these
two; i.e., what is the dose-effect relationship? If we admit that heparin acts in
the blood and on the clotting system, then physiological chemistry can help
pharmacology to answer the following questions: (l) How can we determine the
concentrations of heparin (or heparins if there appears to be more than one
relevant substance)? (2) what is the relevant laboratory parameter to determine
the effect of these concentrations in a sample of the patient's blood?
simple and straighrforward as this may seem, in the case of heparins the
solutions are not immediately apparent. For more than half a century thenecessity
to ffeat patients has induced a pragmatic approach, based on the state ofthe art of
many years ago. The introduction of low-molecular-weight heparins (LMWHs)
renewed the interest in these matters and clearly showed that the traditional
approach was in need of reworking. In recent years, the work of many groups
slowly outlined the contours of what might be a rational approach to heparins
(l). In this chapter we discuss these contours, aware that we suggest solutions
for some of the problems existing in the field, but that have not as yet been
extensively tested in practice.
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The anticoagulant action of crude tissue extracts had already been observed
in the lgth century. It is difficult to decide whether the substances under investiga-
tion have been heparins. Many inhibitory substances can be obtained from tissue
apart from heparin, such as certain phospholipids (2), excess of procoagulant
phospholipid (3), different types of peptides, including fibrin degradation prod-
ucts (4), thrombomodulin (5), Annexin V (6), and so forth. Usually Mclean is
cited as having discovered heparins, but chances are that he purified a phospho-
lipid and that Howell, in modifying Mclean's procedure, may at a given moment
have found a polysaccharide with anticoagulant properties (7). Those interested
in the early history ofheparin are referred to the intriguing article ofJaques (8),
who explains how the attempts of Howell to fit his observations in his theory
of blood coagulation retarded progress in this field. Best ameliorated heparin
production and purification to the extent of making it available as a drug (for the
history of heparin discovery and the heparin units see Ref. 9).
Unfractionated heparin (UFH) trrus has been available since the 1920s'
There consequently is quite some established practice in dealing with these drugs.
Howell, for example, defined a unit of anticoagulant material (heparin or not) as
that amount of material that would retard coagulation of I ml of cat blood so
much that it would only half-clot after one night in the refrigerator. Best adopted
a similar unit for quantifying his heparin preparations and called it the "Howell
unit." This is not only of historical interest because the U.S. Pharmacopoeia
Unit (USP unit), which also is used as the international unit (IU) and in many
national pharmacopoeias, is barely different from the Howell unit, being defined
as that amount of heparin that retards coagulation of I ml of sheep plasma enough
to make it half-clot after I hr at 37'C (8).
Heparin was used as an anticoagulant in the late 1930s. Thus the problems
of clinical dose finding have by now been solved by trial and error. The different
types of heparin used (e.g., bovine lung, pig mucosa) may indeed be different
in many respects. They are, however, sufficiently similar to be compared by the
global clotting test used for the determination of the USP unit. When LMWH
were introduced as a drug by a trial in 1976 (10), it was natural that they were
measured according to the principles established for UFH. These preparations
contain material that, with regard to its action of blood coagulation, is comparable
to UFH, but also other material that acts essentially different from the classical
heparins. Different LMWHs contain these two materials in different proportions.
It is therefore not surprising that the convenient correlation between in vitro
retardation of coagulation of sheep plasma and in vivo pharmacological action
in the human disappeared.
Research in the last few years has made it clear that the traditional way to
approach heparin potency is not the most adequate one for this more complicated
situation. Indeed, there is a considerable amount of confusion arising from
attempts to define LMWHs in terms that were adequate to deal with [IFH. In
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this chapter we propose a more logical approach to the clinical chemistry of
heparins based on recent biochemical data. We will indicate what the differences
are with the existing practice and we will show how existing practice can be
brought in line with the new approach.
I I .  TYPES OF HEPARIN
We recall some of the structural data that are important for the understanding of
the mode of action of heparin. Heparin is a mixture of linear polysaccharides
consisting of alternating iduronic acid or glucoronate units and N-acetylglucos-
amine units joined by glycosidic l-4 linkages. Most of the N-acetyls of the
glucosamine are replaced by N-sulfo groups. Most iduronates are O-sulfated in
their 2-position, most glucosamines in their 6-position [Fig. l, from Barrowcliffe
et al. ( I I )l . This results in a wide variety of different possible monosaccharides.
They occur in almost random order, and the chain lengths can vary from 5 to
100 or more. This chemical diversity is reflected in a diversity of biological
activities. There is one sequence known to date with a specific function: the
pentasaccharide that causes the heparin to bind with high affinity to AT III (12,
and references therein). This binding importantly increases the biological activity
of the inhibitor. The structure of the active pentasaccharide has been confirmed
by organic synthesis (13, l4). Heparins that contain this sequence we call high-
affinity material (HAM).* Heparins that do not contain this sequence conse-
quently do not bind specifically to AT III. This low-affinity material (LAM) as
such is not active in AT Ill-dependent reactions but may influence the action of
HAM by replacing it in nonspecific reactions (see below).
It appears (15-17) that l7 sugar units is a critical chain length: All the
HAM heparins catalyze AT Ill-dependent factor Xa inactivation, but only the
HAM longer than 17 units is capable of catalyzing thrombin inactivation. Heparin
thus contains two subfractions: on the one hand, material with a chain length of
5-17 monosaccharide units (MW 1700-5400), which only catalyzes anti-factor
Xa inactivation and which we call below critical chain length material (BCLM);
on the other hand, material that is longer than 17 monosaccharide units (MW >
5400), which catalyzes both thrombin and factor Xa inactivation and which we
call above critical chain length material (ACLM) (Fig. 2). See also Figure 3 for
a schematic representation of the MW distribution of different heparins.
As far as its anticoagulant properties are concerned, every heparin prepara-
tion, although always highly heterogeneous, can be regarded as composed ofthe
x I USP unit of standard heparin is 6 pg of crude product, i.e., about 2 pg of HAM, or 0.15 nmol.
I U/ml = 0.15 pmol. Due to the uncertainties about the molecular weight and the distribution of
the molecular weight of HAMl4, these are only approximate values.
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Figure 1 Structure ofheparin subunits. (Top) The main repeating disaccharide subunit
of heparin. (Bottom) The pentasaccharide s quence with high affinity for AT III. (From
Ref. I l.)
three functionally different fractions LAM, ACLM, and BCLM (HAM is ACLM
plus BCLM insofar as present). Much of the confusion existing in the field can
be avoided if we realize that unfractionated heparin consists of ACLM and LAM,
whereas LMWH contains a good proportion of BCLM as well (Fig. 3). It is also
essential to recognize that with diminishing molecular weight, the proportion of
BCLM and ACLM shifts in favor of BCLM, but also the HAM (: ACLM +
BCLM) content debreases (18). As a rule, HAM represents a subpopulation of
heparin molecules with a higher mean molecular weight than the total material
09).
Rendering heparin diversity by three different fractions is, of course, both
a simplification of the real situation and a complication of current practice. For
a logical description of the anticoagulant activity of heparin it seems to be
necessary and sufficient.
Apart from anticoagulant action, two other important properties of heparin
are dependent on its molecular weight: its affinity for platelet factor 4 (pf4) and
its pharmacological behavior. The latter will be treated in a separate paragraph.
Platelet factor 4 is a protein contained in the ct-granules of blood platelets
and released when platelets are activated. Its physiological function is unknown.
It binds to heparin molecules, HAM and LAM alike, with an affinity dependent
on the chain length (20). From l0 to 16 saccharide units, the affinity gradually
increases; above 16 units (MW -4800) the affinity is constant and high. This
cHrosos-
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Figure 2 Subdivision of heparin species.
means that all ACLM binds maximally and is effectively neutralized. Half-
neutralization requires less than I mol/mol, and full neutralization is observed
when the ratio of pf4 to heparin molecules is 3: I (2 I ). For all practical purposes,
the binding to ACLM may be considered irreversible; it is so strong that AT III
cannot effectively compete with pf4.
BCLM escapes neutralization to a great extent because it binds to pf4 much
less tightly than ACLM does. It should be stressed that pf4 binding is not
dependent on the specific pentasaccharide sequence; i.e., heparin molecules of
the LAM family with a sufficiently high chain length bind as tightly as ACLM
(20). One of the ways in which LAM can influence heparin activity in situations
where platelets are activated is precisely by their binding to pf4, which then will
no longer be able to bind the catalytically active species ACLM. This may
explain the potentiating effect of LAM on HAM (22).
The platelet activation that inevitably accompanies venipuncture and han-
dling of blood samples for the clinical laboratory will always cause some pf4 to
be released, which then will neutralize a certain amount of ACLM in the sample.
Van Putten showed that 0.185 -10.072 U/ml of UFH activity on average is lost
in plasma samples in the clinical laboratory (23). Apart from that, some pf4 is
released from the endothelium after injection of heparin (24).
As heparin is a highly charged molecule, it will bind with a certain affinity
to different positively charged plasma proteins, such as histidine-rich glycopro-
tein (25) and vitronectin, especially after the latter has been modified by thrombin
(26-28). This binding is of comparable strength as that of AT III but yet not
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Figure 3 Schematic representation of the molecular weight distribution of different
heparin species. (From Ref. 64')
dependent on the presence of the active pentasaccharide. The HAM in a given
heparin will distribute over AT III and other heparin-binding proteins in plasma'
rne I-nv present in that heparin will bind to the other proteins. Both AT III
and the other proteins occur in molar excess over heparin in therapeutic and
froptrytactic dlsages (Table l). The amount of HAM that binds to AT III
ietermines the observed heparin activity. It depends on the partition of the
heparin between AT III and the other proteins, which in its tum is determined
by( l ) theamountandthehepar inaf f in i tyofATl l lascomparedtotheamount
unA'ufnnity of the other proteins, and (2) the number of heparin-binding sites on
the other proteins that are occupied by LAM. This has two important conse-
quences. First, the amount of heparin bound to AT III will be proportional to the
AT III concentration, even though far from all AT III molecules will bind a
heparin molecule. This is because the concentration of AT III relative to the
concentration of other heparin-binding proteins will determine the probability of
a free heparin molecule being bound to AT III (29)' Second, LAM will occupy
a certain number of binding sites for heparin on the other proteins and so make
HAM material available for binding to AT III. This situation may again explain
the observation that addition of LAM to HAM increases the effect of the latter
(2D.
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Table 1 Data on Some Clottine Factors and Inhibitors
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Protein Symbol
Conc. MW
(rrM) (kDa)
Kd Peak
(nM) (nM)
Prothrombin
Factor X
Factor IX
Antithrombin III
Heparin cofactor II
Histidine-rich glycoprotein
Vitronectin
Platelet factor 4
F.II
F .X
F.IX
AT III
HC II
HRGP
Vitr.
pt4
z
0 .  l 8
0.07
2-3
I
l - 1 . 5
5-5.5
66
55
70
58
65
75
75
40
5
l 0
7
7
0 .3
200
l 2
L
K6 is the dissociation constant for UFH in nM; kDa = kilodalton.
Peak is the approximate peak concentration of the activated factor attained in clotting plasma without
heparin. For pf4 it is the amount released into plateletrich plasma during coagulation.
I I I .  SPECIFIC ACTIONS OF HEPARINS
It is essential to distinguish between specffic and composite biological effects of
heparin. The specific effects are its catalytic action on a number of well-defined
biochemical reactions. The composite effects are the consequences of the specific
effects in composite reaction systems. Enhancement of thrombin inactivation by
AT III is one of the specific effects of heparin; prolongation of the APTT and
prevention of thrombosis are two examples of composite effects.
The relative contributions of the different specific activities to the various
composite effects are not exactly known as yet. There is no reason to assume
that one composite action (e.g., the bleeding tendency) will depend on the
specific effects (antithrombin activity, anti-thrombin Xa activity) in the same
manner as another (e.g., the antithrombotic effect). This is the rationale behind
the search for heparins with a more favorable distance between therapeutically
active and potentially dangerous doses.
The set of specific activities of heparins is relatively large. All clotting
proteases are involved (Kallikrein, Factors XIIa, XIa, Xa, IXa, and thrombin)
(30-33) and two different inhibitors (AT III, HC II (34 & 35)). In practice, we
do not have to deal with all of them. The contribution of HC II must be considered
to be negligible (36,37) except at high concentrations of heparin, such as are
seldom encountered (>5 U/ml). The effect of heparin on the inactivation of
clotting factors XIa, XIIa, and kallikrein is much smaller than that on the other
factors and probably without consequences for heparin action (38). Also, contact
activation presumably is only of minor importance in hemostasis and thrombosis
(39). These inhibitions therefore need not be considered further. We are thus left
60
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with the inactivation of thrombin, factor Xa, and factor IXa as the important
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way as the thrombotic tendency does. For the moment we can only prove that
the existing overall tests are not suitable candidates.
There is a way out of this dilemma: On basis of the specific actions on
thrombin and factor Xa, we can determine the concentrations of ACLM and
BCLM separately. This opens the possibility of studying pharmacokinetics of
heparin directly, without the confusing need to compare one composite effect
(e.g., APTT) to the other (e.g., bleeding).
In order to understand the quantitation of heparins on the basis of this
catalytic action, we must briefly discuss the kinetics that govern this type of
reactions. x
The inactivation of clotting enzymes by AT III in plasma is a bimolecular
reaction (E + A4 f. According to standard chemical kinetics, its reaction
velocity is given by u, : kAp,. The concentration of AT III in plasma is much
higher than the highest concentration of thrombin, the most abundant enzyme in
clotting plasma (AT III: 2.5 p"M, thrombin about 0.2 pM at its peak). Therefore,
A, can thus be considered constant during a decay experiment, so that the decay
velocity of the enzyme can be given by v, : AFu or v : to""E,, where ka.. :
kAo.
The time course of E can than be given by Et : Eo€-rd""; i.e., the enzyme
decays semilogarithmically. The half-life time is inversely proportional to k6".,
therefore, trr: O.693lko...f The dimension of ko"" thus is inverse time, usually
expressed in min-r. Heparin catalyzes the above reaction. Although the mecha-
nism of catalysis may be complex (41), its effect is simple: decrease of the half-
life time and increase of k0"". The decay constant increases proportionally to the
AT III concentration and to the concentration of heparin: k*, : fr,4l1. This
proportionality can be used to define a unit of heparin activity (see below). It
should be noticed that H indicates the concentration of active heparin. For the
decay of factor Xa, the HAM molecules count; for the decay of thrombin, only
the ACLM fraction counts.
Heparins also have a number of biological activities that are not related to
their anticoagulant action. They influence the growth of endothelial (42) and
smooth muscle (43) cells. They also cause the release of lipoprotein lipase and
tissue factor pathway inhibitor (TFPI) (44) from the vessel wall. They are neither
specific nor composite effects in the sense discussed above. Here we will restrict
ourselves to the effect of heparin on the blood coagulation process in plasma,
because that is the basis for the assessment of the heparin effect in the clinical
8In the reaction equations E stands for enzyme (thrombin, factor Xa, etc ), A is AT III, 1 is inactive
product. In the kinetic equations the same letters stand for the concentrations of these substances.
The subscripts denote the time; Es is the enzyme concentration at zero time, and so forth.
tBecause the natural logarithm of % equals 0.639
29
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below).
IV. THE MODE OF ACTION OF HEPARINS ON THROMBIN
CENERATION
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Figure 4 The clotting mechanism. (trft) The proteolytic interactions. (Right) The
accelerators and feedback reactions included. Ovals indicate a phospholipid surface.
(Open anows) Proteolytic activation. (Closed arrows) Chemical conversion. (Dashed
arrows) Enzymatic action. (Modified from Ref. 65.)
binding of thrombin to thrombomodulin and the activation of protein C. The
important consequence for the mode of action of heparin is'that accelerated
thrombin disappearance in the earlier phases of the reaction will prevent the
feedback activation of factors V and VIil (48-53).
I We devised methods to obtain thrombin generation curves and to determine
I the halflife of thrombin with great precision. Via a mathematical procedure we
I could then, from these data, calculaie the time course of prothrombin conversiond (29, 54). To our surprise, it appeared that in the extrinsic system the bulk of
heparin action must be attributed to its antithrombin activity (Fig. 5). This was
true not only for UFH, but also for most LMWHs! It thus appeared that the
enhanced inactivation of factor Xa that is undoubtedly caused by UFH and is
even more important in LMWHs did not influence the coagulation mechanism
very much. The reason for this unexpected finding is that factor Xa does not act
_ 
as such, but as a member of the prothrombinase complex, a tripartite complex of
factors Xa and Va and phospholipid. The member with the lowest concentration
determines the amount of prothrombinase that can be formed. Full prothrombin
conversion is observed at very low concentrations of prothrombinase: 0.3 nM.
The peak concentration of factor Xa is about 12 nM, but factor Va is rate
limiting in clotting plasma (51, 55). Factor Xa therefore is present in large excess,
{'
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Figure 5 Inhibition of the extrinsic and the intrinsic thrombin and prothrombinase
formation by heparin. (Modified from Ref. 53')
and quite a lot of factor Xa inhibition can take place before prothrombinase is
inhibited.
In the intrinsic system the inhibition of prothrombin conversion is more im-
portant than in the extrinsic system. This cannot be attributed to inhibition of fac-
ior Xa because the role of that factor is the same in the two systems. It is explained
by the fact that the feedback activation of factor VIII is more sensitive to inhibition
oi the thrombin involved than that of factor V. The tissue factor-factor VII(a)
complex of the extrinsic system is not inhibited by heparin-AT III. So in the intrin-
sic system the generation of factor Xa is inhibited but in the extrinsic system it is
not. Further studies showed that the lag time of thrombin generation in the intrin-
influence: This test measures the lag.time of thrombin generation in the intrinsic
system. It therefore measures the time necess:[y for enough factor VIIIa to be
formed. In other words, it is influenced by the inhibition of minute amounts of
thrombin that are formed during the lag phase (Fig' 6)'
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Figure 6 Early phase of thrombin formation in plasma. (Top) Extrinsic system (throm-
boplastin time). (Bottom) Intrinsic system (APTT). (From Ref. 66.)
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In the extrinsic system no lag time of thrombin formation is seen with or
without heparin. The slight prolongation of the PT that is observed is due to the
fact that in the presence of heparin it takes longer to form a sufficient amount of
thrombin to clot the fibrinogen present, even though thrombin formation starts
directly after recalcification (53).
Compared to UFH, LMWHs are enriched in BCLM This means that their
anti-factor Xa activity will be relatively more important than their antithrombrn
activity. Especially when compared to a heparin standard. this effect seems
impressive. By definition, I USP unit of standard heparin contains I USP unit
of anti-factor Xa activity and I USP unit of antithrombin activity. This definition
tends to obscure the fact that the anti-factor Xa activity in plasma, both in the
presence and in the absence of ACLM, is always about 3 times lower than the
antithrombin activity. (Table 2). The only way to enhance the anti-factor Xa
activity in plasma relative to its antithrombin activity is by adding BCLM. That
is what happens when LMWHs are administered. But enhancing the anti-factor
Xa activity in plasma is an efficient means of inhibiting prothrombin conversion.
Because factor Xa is present in excess over factor Va in clotting plasma, one can
inhibit some 907o of the factor Xa activity without altering the velocity of
prothrombin activation. This does not mean that it will not work. Pure BCLMs,
like the synthetic pentasaccharide, can be given in such high amounts as to be
efficient anticoagulants and hence efficient antithrombotics, but relatively high
amounts are necessary to be effective (57). We observed that one of the LMWHs,
in which the ratio BCLM/ACLM was higher than in the others, did show signifi-
cant inhibition of prothrombinase (58). Indeed, there is no reason why they
should not.
Other effects than the mode of action in the clotting system in platelet-poor
plasma in vitro will determine whether LMWHs are useful antithrombotics. The
relative enrichment of BCLM over ACLM in LMWHs may not have much
influence in vitro; in vivo two circumstances favor the influence of the BCLM
injected wirh LMwHs. First, the biological half-life time of BCLMs is signifi-
Table 2 Influence of Heparins on the Decay Constant of Thrombin and Factor Xa
in Plasma
Heparin Factor Xa Thrombin
No heparin
ACLM
BCLM
UFH
Penta
0.49
4.25
't.24
l . 5 l
l  3 .65
-0
The figures are in min I per pM AT III (no heparin) or in min ' per pM AT lll per pg heparin per
ml olasma
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cantly longer than rhat of ACLMs (60). By rhis mechanism the BCLM fracrion
of a LMWH injected will survive longer in the circulation than the ACLM
fraction, so that a "fractionation in vivo" takes place. The ratio of BCLM/
ACLM in the circulation increases with time after injection. Second, activated
platelets release PF4, which very efficiently neutralizes ACLM but not BCLM.
Hemostasis and thrombosis inevitably entail platelet activation, hence pF4 re-
lease. In this way BCLM, but not ACLM, may escape neutralization at precisely
those sites where thrombosis occurs.
V. HOW TO ASSESS THE EFFECT OF HEPARIN IN A PATIENT
As stated in the Introduction, it is of the utmost importance to dispose of a test
that ex vivo, on a sample of the patient's plasma, reflects the extent of anticoagu-
lant action in vivo. such a test does not as yet exist, but here we would like to
point to a possible candidate. current practice provides only indirect measures
that may or may not correlate with the antithrombotic effect. The prothrombin
time correlates with the antithrombotic effect brought about by oral anticoagula-
tion. The APTT indicates the effect of heparin, and so forth. The fact that
different drugs, at effective concentrations, have largely different influences on
these tests already indicates that neither of them can be the universal parameter
that we should like to obtain. The reason for this is easy to imagine. A clotting
time is essentially the time it takes before a thrombin burst takes place (60). It
does not necessarily contain information about the magnitude of that burst,
although it may of course do so (as in the case of the Aprr at varying heparin
concentrations).
It can be safely assumed that the enzymatic action of thrombin is essential
in hemostasis and thrombosis and that the amount of thrombin that can act in a
hemostatic or thrombotic process determines the magnitude of the hemostatic
and thrombotic response (39). So what we want to know is the amount of
thrombin formed-more precisely, the amount of thrombin formed and the time
that it has the opportunity to act.
Thrombin is an enzyme, and one may expect that I nM of an enzyme
acting for l0 sec will have the same effect as l0 nM acting for I sec. This means
that the product of time and concentration determines the effect of thrombin.(The mathematically correct description is: the time integral of the thrombin
generation curve.) A normal amount of thrombin that persists longer because of
a congenital lack of antithrombin III may cause thrombosis. A tendency to
thrombosis can be remedied by lowering the amount of thrombin formed via oral
anticoagulation or by making a normal amount of thrombin disappear faster than
normal via heparin administration.
This demonstrates that the product of concentration and time is an imponant
variable. we called itthe thrombin potential ep) (61).It is not a new one; the
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area under the thrombin generation curve, introduced before 1950 (62), is pre-
cisely the same thing. The TP has the dimension of time multiplied by (thrombin)
concentration; its value in normal plasma is around 500 nM min (61). It may
depend on the experimental conditions, such as intrinsic or extrinsic clotting, but
varies little if at all with thromboplastin concentratlon'
In our experience, all antithrombotics, including those that have little
influence on the APTT (e.g., dermatan sulfate), in clinically relevant doses
invariably bring about a significant decrease of the TP'
One can think of thrombin-mediated antithrombotic medication as the
administration of a drug to decrease the TP value under the threshold limit of
thrombogenesis but remaining above the threshold of hemostasis. It remains an
open question whether the nature of the drug has an influence on the thresholds.
Those who are looking for the ideal anticoagulant, one that prevents thrombosis
without inhibiting hemostasis, tacitly assume that this is possible. In our opinion,
this is not very likely. We think rather that the differences between drugs such
as UFH and LMWH are largely due to different pharmacological properties,
which means that they can be maintained more easily in the required range of
plasma levels. Secondary circumstances may also intervene. Drugs that act via^heparin 
cofactor II (dermatan sulfate, lactobionic acid) can hardly be overdosed
because the plasma level of heparin cofactor Il is lower than that of prothrombin,
so the TP cannot be inhibited beyond a certain level'
We recently developed an easy way to determine the TP in a single spectro-
photometric test (63). In this test an inefficient chromogenic substrate for throm-
tin is added to the plasma, before coagulation is triggered. The thrombin that
generates and disappears will continuously convert some of the substrate' but
n"u". *or" than about l07o of the total amount added. In this way the final
amount of chromogenic substrate converted is proportional to the concentration-
time integral of thrombin.
VI. HOW TO MEASURE HEPARIN LEVELS
It is current practice to express the potency of a given heparin by comparing it
to that of a standard preparation in a given clotting test. When heparin is expressed
in USP units, it is assumed to be compared to the effect of a standard preparatlon
on the clotting of sheep plasma. The outcome of any clotting test is a composite
effect of heparin. Different combinations of ACLM and BCLM may add up to
the same finat ffict on such a test. A pure BCLM, like the synthetic AT
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uFH. An equivalent effect of two doses of different LMWHs in one test will not
necessarily mean an equivalent effect in another test or in an in vivo situation,
because LMWHs are mixtures of two fundamentally different heparins (ACLM
and BCLM) that cannot be measured with the same yardstick.
Therefore, the potency of a heparin, assessed by comparison via a clotting
test, is ill defined. It depends both on the nature of the standard and on the
method of comparing the activities. we calculated, for example, that the activities
given on the labels of LMWH vials, which are based on the current method of
estimating anti-factor Xa activity (in the absence of Ca2+ ions), overestimate the
real heparin activity in plasma | .37 -l .l6 times . It is therefore necessary to define
a new type of unit that allows one to express heparin activity in a standard,
method-independent way.
vary so much that the behavior of heparins becomes quite different in each. The
presence or absence of ca2+ is often at the basis of confoundins results.
The recognition of the specific actions of ACLM and BCLfr on anti-factor
again, via the specific anti-factor Xa activity of the HAM injected, in pg of
material.
Because the decay constant, t0"., is proportional to the AT III concentration
and because heparin increases /<0". proportionally to the HAM concentration, we
can define a standard, method-independent unit as: one unit of HAM (or anti-
factor xa) activity is that amount of HAM that, in plasma with n p,M AT III
increases ko"" of factor Xa by n min | .
Analogously we define: one unit of ACLM (or antithrombin) activity is
that amount of ACLM that, in plasma with n p,M AT III increasesko""of thrombin
by n min- t .
It is important to note that the reaction conditions are defined to be as close
as possible to the conditions in which heparin acts in vivo: normal plasma, diluted
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as fewaSthec i r cums tancesa l l ow ,andano rma lconcen t ra t i ono f f reeCa2*
( 1 . 1 5 - 1 . 3 2  m M ) .
Any LMWH preparation now can be assigned two specific 
activities (Sno^
and Su,1^), which are titffy the number of. (HAM or ACLM) activity-units
i". #ii"*"ight (pg). The'siecific activity allows rhe 
derermination of hepartn
concentrations in plasma' If we encounter a plasma sample 
in which we measure
an anti-factor Xa activity of Z units/ml' then we can calculate 
the amount of HAM
material as being ZlSn^^l,t"gtmL Analogously' from the antithrombin 
activity (say
0), we may calculat" int eCt-tvl content as QiS"''' Finally' 
we can obtain
eCLNa from HAM minus ACLM'
For the adoption ofthe new unit' no important changes in evervday 
labora-
tory practice are iequired. Any well-designed. antithrombin 
test is dependent on
thrombin breakdown u"lo"i'y tnty' hente will measure ACLN'I' 
Likewise' good
antifactor Xa activity tests ;ill only *tu'utt factor Xa breakdown 
velocity'
Theresul tsofsuchmonospeci fc testscanbeexpresseddirect ly instandard
independenr unirs. To;;;"J',"""'should. calibrare the 
test against a ko., (t,,r)
determination or agalnst a heparin preparatlon whose potency 
is known in terms
o fS lun i t s .Th i sb r i ngsback thehepa r i ns tanda rd 'bu t th i s t ime i t i sno longe r
thestandardthatdef inestheuni t 'Thestandardisnowatool forcal ibrat ionthat
canbeabandonedbythosewhoprefer tomeasureka", ( t to)d i rect ly . 'Hencethe
definition of the unit is no longei dependent on the standard 
or on the method
iV *ttl"tt the standard and the sample are compared'
A suitable ACLM preparatio; can be used to calibrate both anti-factor 
Xa
tests intermsofSlUXaandant i thrombintests intermsofSlUl la .Todetermine
wether the test under observation is indeed monospecific, 
a BCLM_ standard can
be used. A monospecific antithrombin test will not react 
to BCLM at all' A
monospecific anti-factor Xa test will give the same result 
with an ACLM and a
BCLM standard' ' d out' monospecific anti-factor XaOnce the suitable calibrations are calrle
t e s t s c a n t h e n b e u s e d t o d e t e r m i n e t h e H A M l e v e l i n s a m p l e s ( i n p r , g / m l o f
plasma, if the specific activity of the HAM material injected is known)' and
monospecific anti-thrombin tests can be used to determine 
ACLM levels (again
in pg/ml of plasma, if the specific activity of the ACLM 
material injected is
known)'
vll .  coNSEQUENCES FOR HEPARIN PHARMACOKINETICS
AND PHARMACODYNAMICS
The most compelling question about LMWHs was whether they 
were better drugs
than uFHs. A numbei of clinical studies, referred to in other 
chapters, seem to
foint ln that direction' The next question 
is how to explain this phenomenon'
The bottom line of our biochemical studies on the mechanism 
of action of
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heparins in plasma is that LMWHs are rather more like UFHs than one would
like to admit at first sight. Anyhow, as discussed above, the fact that thrombin
is inhibited seems to be more important for thrombosis and hemostasis than the
mechanism responsible for this inhibition.
Rather than in the biochemistry per se, we think that the difference between
LMWHs and UFHs is to be found in their different pharmacological behavior.
This makes it compulsory to have exact information about this behavior. A large
amount of data is available in this field. Interpretation, however, sometimes
poses a problem. It is not always possible to distinguish between effects on the
blood levels of active materials and the consequences of these levels for functional
clotting tests.
Often the effect of heparin on a blood coagulation test has been investigated
rather than the amount of heparin present. The existing data on antithrombin
and anti-factor Xa activity levels after heparin injection contain the relevant
information. When expressed in international (: USP) (antithrombin or anti-
factor Xa) units, they give levels that are proportional to, respectively, the
ACLM and the HAM levels. The proportionality factor is different for the two
substances, and the BCLM levels cannot immediately be calculated from the
difference of the two curves. This is regrettable because the presence of BCLM
constitutes the essential difference between UFH and the LMWHs, and the most
important differences between the LMWHs are in the ratio ACLM/BCLM. The
use of standard independent units and the determination of specific heparin
activities enable us to assess separately the levels of ACLM and BCLM in the
circulation. This means that we can discuss heparin pharmacokinetics in terms
of concentrations of active molecules. Only then can we in a meaningful way
discuss the effects of these concentrations on composite phenomena such as
clotting times, thrombin formation, thrombus growth, and bleeding tendency. In
this way it is possible to separate heparin pharmacokinetics from its pharmacody-
namics.
It may be possible that the specific activity, when expressed per mole of
active material (i.e., HAM for anti-factor Xa activity), is very similar for highly
different heparin preparations. In six UFH and LMWH preparations of different
origin, in which the specific activities ranged from 0.71 to 4.25 SIU Xa/pg crude
material, the mean specific activity was 87 -f 13 SIU Xa per nM HAM.
In a completely analogous way, we can determine the specific antithrombin
activity of a heparin. Again, from the specific activity of the crude material, one
can calculate the specific activity per mole of active heparin species, i.e., of the
ACLM fraction. It again seems that the specific antithrombin activity of ACLM
molecules could be similar for different types of heparin (3OS * 54 SIU IIa per
nM ACLM).
The constant specific activity at first sight may seem to contradict earlier
findings that reported a gradual change of potency of heparin preparations with
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meanmolecularweight(seeRef. l l foradeta i leddiscussion) .However. in these
publications the activities were expressed 
per unit weight of crude material'
whichdoesnot taKelntoaccount that t t reamountofact ivemater ia ldecreases
proportional to tne mean molecular weight of the 
preparation ( l8)' If our conlec-
ture on the identical 'p"tiAt ut' iuity oiall HAM 
is irue' then the SIU Xa value
would indicate tne nu;-er 
"i"",*" 
HAM molecules in the sample independent
of the type of heparin'G"iJ Analogously' 
the ACLM level can be obtained
o"*'l:.tJJotfir"rffi ir is necessary that the heparin that is injected is well
characterized as to its fiott'trnitut actions 
on the clotting system ex vivo'
The following data are minimally required:
: HAM)'
:erial around the 5400-Da lim\t' i'e'' Vo
he HAM fraction'
'ACLM fraction' Optionally the spectnc
t and the BCLM fractions may be given'
when these data are known, it is possible to 
express the results of common
/ tests in terms of circulating concentra-
parin' Also' these data will give insight
ether the different LMWH preparations
differ only in their relative contents or
n is given of the pharmacology of the
the Li{WHs can we start to answer the
coagulant actions of heparin for its antt-
thrombotic effects'
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